FLAURA2 shows early EGFR ctDNA clearance is prognostic but does not predict benefit from adding chemotherapy to first-line ...
A retrospective single-center analysis of 452 Chinese patients with non-small cell lung cancer associated compound and ...
Clostridium botulinum bacteria produce a potent neurotoxin called botulinum toxin, which causes the serious illness botulism. The toxin attacks the nervous system, leaving the body unable to control ...
ArriVent's firmonertinib Phase 1b data published in Cancer Cell, targeting EGFR PACC mutations resistant to standard ...
ArriVent BioPharma, Inc. announced the publication of FURTHER Phase 1b (FURMO-002; NCT05364073) results of firmonertinib in Cancer Cell, highlighting the preclinical and clinical findings supporting ...
EGFR PACC-mutant NSCLC is one of the largest underserved patient populations within EGFR-driven lung cancer. Accounting for approximately 12% of EGFR-mutant tumors, these patients currently have no ...
Researchers at Harvard University and affiliated institutions developed a new, easy-to-use, web-based tool that simplifies ...
FURTHER shows firmonertinib 240 mg achieved 68% ORR and 16-month PFS in advanced EGFR PACC-mutant NSCLC, with intracranial ...
Researchers in a Mayo Clinic-led study have shown how to detect a broad range of DNA mutations in noncancerous human tissues ...
Tropic Biosciences UK Ltd has applied for permission to market in England a GM banana that has been gene-edited not to go ...
Inherited changes in the architecture of the human genome, far larger than the single-letter mutations that have dominated ...
EU application is back under EMA review for EGFR-mutated NSCLC. Find out what this resubmission means for patients today.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results